0001104659-26-058234
SEC filingLiquidia Corporation reported its third consecutive quarter of profitability for Q1 2026, driven by $129.9 million in YUTREPIA net product sales, $52.9 million net income, and $71.2 million adjusted EBITDA, with cash increasing by $32.1 million to $222.8 million as of March 31, 2026.
Liquidia’s Q1 2026 results mark a decisive inflection point: the company achieved its third consecutive quarter of profitability, driven entirely by commercial execution of YUTREPIA, which launched in June 2025 after FDA approval on May 23, 2025. Product sales of $129.9 million — representing the first full quarter of recognized revenue — were the sole driver of top-line growth, as no product sales occurred in Q1 2025. Gross margin was robust, with cost of product sales at $11.1 million, implying an approximate 91% gross margin. Net income of $52.9 million reversed last year’s $38.4 million loss, supported by disciplined R&D spend ($12.6M, up $5.6M YoY but still below SG&A) and sharply higher non-GAAP adjusted EBITDA ($71.2M), which grew 2.6x sequentially from Q4 2025’s $27.3M — signaling operating leverage as commercial infrastructure scaled. Cash increased $32.1M Q/Q to $222.8M, confirming self-funding capacity without dilution or debt drawdowns. Management highlighted sustained uptake across PAH and PH-ILD, citing >4,500 unique prescriptions and ~3,750 treated patients through April 30, 2026, with strong prescriber engagement (980 total, 270 prescribing to ≥5 patients). The earnings release explicitly ties financial performance to YUTREPIA’s role as the ‘preferred inhaled prostacyclin of choice,’ while also emphasizing ongoing clinical investments — including the pivotal Phase 3 Re-Spire study for L606 in PH-ILD — funded organically. Importantly, the press release cautions that commercial continuity remains subject to ongoing patent litigation with United Therapeutics seeking injunctive relief, a material legal risk not quantified but explicitly flagged as potentially blocking sales.